Pulmonary Hypertension in Hypersensitivity Pneumonitis

Overview

The investigation serves the identification of pulmonary hypertension (PH) among patients with hypersensitivity pneumonitis (HP). The exact prevalence of PH in HP is unknown. Data from South America indicate that the prevalence of pre-capillary PH amongst patients with HP is higher than 20%. There are no reliable data from Europe so far. According to the investigators previous analysis, more than 400 HP patients have participated in pulmonary rehabilitation at least once in the past 10 years at Klinikum Bad Gleichenberg (Rehabilitation Center for Agricultural Workers in Austria). This collective of patients is to be invited to participate in the study.

A diagnostic algorithm will be applied in the clinical trial, in the case of clinical suspicion the diagnosis of PH will be confirmed by right heart catheterization. Besides the determination of the prevalence of PH in patients with HP the investigators aim to assess the reliability of non-invasive methods (e.g. Echocardiography, ECG…) to predict PH.

Full Title of Study: “Recognition of Pulmonary Hypertension in Patients With Hypersensitivity Pneumonitis”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 2020

Interventions

  • Diagnostic Test: Right heart cathetarization (in case of suspected PH)

Clinical Trial Outcome Measures

Primary Measures

  • Prevalence of pulmonary hypertension
    • Time Frame: 4 year

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with confirmed Hypersensitivity Pneumonitis
  • written consent
  • Age: 18-90 years

Exclusion Criteria

  • severe impairment of the general health condition
  • pregnancy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Medical University of Graz
  • Collaborator
    • Ludwig Boltzmann Institute Lung Vascular Research
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Horst Olschewski, MD, Principal Investigator, Medical University of Graz

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.